Creating a large database of T cell receptors and their interactions with cancer antigens

Who could benefit from this research

What this research studies

This research focuses on understanding how T cell receptors (TCRs) recognize tumor antigens presented by MHC molecules, which is crucial for developing effective immunotherapies for cancer. By leveraging advanced machine learning techniques, the project aims to generate a comprehensive dataset of TCR-pMHC pairs from both human and mouse sources. The research will involve high-throughput methods to match TCRs with their corresponding antigens, ultimately enhancing our ability to predict and design targeted cancer treatments. Patients may benefit from improved immunotherapy options as a result of this work.

Why it matters

Where this research is happening

• University College London
  London, United Kingdom Active

Researchers

• Principal investigator: Quezada, Sergio — University College London
• Study coordinator: Quezada, Sergio

Related research

Other NIH-funded projects on the same topics.

• 7-marker protein test to predict NSCLC response to anti-PD-1 therapy

  A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11552207

• Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer

  This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11467904

• Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype

  A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.

  NIH research University of Texas Hlth Sci Ctr Houston · Houston, United States · NIH-11433470

• Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging

  A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.

  NIH research Emory University · Atlanta, United States · NIH-11422847

• ATM kinase as a target to help NSCLC with brain metastases respond to treatment

  A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.

  NIH research Yale University · New Haven, United States · NIH-11417454

• Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies

  A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11416431

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.